49 related articles for article (PubMed ID: 38662226)
1. Clear cell and non-clear cell renal cell carcinoma in young adults: clinicopathological features, survival outcomes and prognostic factors.
Xue Z; Tang S; Ou J; Fang Y; Qiu M; Hong K; Tian X; Zhang H; Liu C; Ma L; Zhang S
World J Urol; 2024 May; 42(1):364. PubMed ID: 38819448
[TBL] [Abstract][Full Text] [Related]
2. Perioperative Considerations in Metastatic Renal Cell Carcinoma.
Flavin K; Vasdev N; Ashead J; Lane T; Hanbury D; Nathan P; Gowrie-Mohan S
Rev Urol; 2016; 18(3):133-142. PubMed ID: 27833463
[TBL] [Abstract][Full Text] [Related]
3. Nephrectomy in metastatic renal cell carcinoma.
Campbell SC; Flanigan RC; Clark JI
Curr Treat Options Oncol; 2003 Oct; 4(5):363-72. PubMed ID: 12941196
[TBL] [Abstract][Full Text] [Related]
4. Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis.
Jiang HM; Wei JH; Zhang ZL; Fang Y; Zhou BF; Chen ZH; Lu J; Liao B; Zhou FJ; Luo JH; Chen W
Int Urol Nephrol; 2016 Feb; 48(2):191-9. PubMed ID: 26589610
[TBL] [Abstract][Full Text] [Related]
5. The survival benefit of metastasectomy for metastatic non-clear cell renal cell carcinoma: a retrospective cohort study.
Dai J; He B; Zhang Y; Zhang H; Hu X; Xu L; Ni Y; Zhang X; Sun G; Zeng H; Shen P; Liu Z
World J Urol; 2024 Apr; 42(1):259. PubMed ID: 38662226
[TBL] [Abstract][Full Text] [Related]
6. Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?
Marvaso G; Corrao G; Oneta O; Pepa M; Zaffaroni M; Corso F; Gandini S; Cecconi A; Zerini D; Mazzola GC; Augugliaro M; Cossu Rocca M; Verri E; Cattani F; La Fauci F; Bergamaschi L; Luzzago S; Mistretta AF; Musi G; Nolè F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Clin Transl Oncol; 2021 Aug; 23(8):1717-1726. PubMed ID: 33687659
[TBL] [Abstract][Full Text] [Related]
7. Outcomes for Patients after Resection of Pulmonary Metastases from Clear Cell Renal Cell Carcinoma: 18 Years of Experience.
Procházková K; Vodička J; Fichtl J; Krákorová G; Šebek J; Roušarová M; Hošek P; Brookman May SD; Hes O; Hora M; Třeška V
Urol Int; 2019; 103(3):297-302. PubMed ID: 31434090
[TBL] [Abstract][Full Text] [Related]
8. Surgical treatment of atypical metastasis from renal cell carcinoma (RCC).
Antonelli A; Arrighi N; Corti S; Legramanti S; Zanotelli T; Cozzoli A; Cunico SC; Simeone C
BJU Int; 2012 Dec; 110(11 Pt B):E559-63. PubMed ID: 22639956
[TBL] [Abstract][Full Text] [Related]
9. Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma.
Tosco L; Van Poppel H; Frea B; Gregoraci G; Joniau S
Eur Urol; 2013 Apr; 63(4):646-52. PubMed ID: 23041360
[TBL] [Abstract][Full Text] [Related]
10. The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis.
Thomas AZ; Adibi M; Slack RS; Borregales LD; Merrill MM; Tamboli P; Sircar K; Jonasch E; Tannir NM; Matin SF; Wood CG; Karam JA
J Urol; 2016 Sep; 196(3):678-84. PubMed ID: 27036304
[TBL] [Abstract][Full Text] [Related]
11. Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.
Lee CH; Voss MH; Carlo MI; Chen YB; Zucker M; Knezevic A; Lefkowitz RA; Shapnik N; Dadoun C; Reznik E; Shah NJ; Owens CN; McHugh DJ; Aggen DH; Laccetti AL; Kotecha R; Feldman DR; Motzer RJ
J Clin Oncol; 2022 Jul; 40(21):2333-2341. PubMed ID: 35298296
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies.
Stühler V; Herrmann L; Maas M; Walz S; Rausch S; Stenzl A; Bedke J
World J Urol; 2022 May; 40(5):1175-1183. PubMed ID: 35217885
[TBL] [Abstract][Full Text] [Related]
13. STROCSS 2021: Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery.
Mathew G; Agha R;
Ann Med Surg (Lond); 2021 Dec; 72():103026. PubMed ID: 34820121
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of nivolumab plus ipilimumab as first-line therapy for primary tumors in patients with renal cell carcinoma.
Kikuchi H; Osawa T; Matsumoto R; Abe T; Maruyama S; Harabayashi T; Miyata H; Kashiwagi A; Ikeshiro S; Sazawa A; Fukui R; Morita K; Takeuchi I; Hori K; Yamashita N; Minami K; Mochizuki T; Murai S; Shinohara N
Urol Oncol; 2022 Jan; 40(1):13.e19-13.e27. PubMed ID: 34716079
[TBL] [Abstract][Full Text] [Related]
15. The Morphological Spectrum of Papillary Renal Cell Carcinoma and Prevalence of Provisional/Emerging Renal Tumor Entities with Papillary Growth.
Lobo J; Ohashi R; Helmchen BM; Rupp NJ; Rüschoff JH; Moch H
Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680535
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
